Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome

被引：0
|
作者：
Glauser, T
Kluger, G
Sachdeo, R
Krauss, G
Perdomo, C
Arroyo, S
机构：
[1] Cincinnati Childrens Hosp, Cincinnati, OH USA
[2] BHZ, Vogtareuth, Germany
[3] St Peters Univ Hosp, New Brunswick, NJ USA
[4] Johns Hopkins Med Ctr, Baltimore, MD USA
[5] Eisai Med Res, Ridgefield Pk, NJ USA
来源：
EPILEPSIA | 2005年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：408 / 408
页数：1
相关论文
共 50 条
  • [41] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results from Open-label Extension Trial (GWPCARE5)
    Halford, Jonathan
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Gunning, Boudewjin
    Checketts, Daniel
    Roberts, Claire
    Thiele, Elizabeth
    NEUROLOGY, 2018, 90
  • [42] Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis
    Lattanzi, Simona
    Brigo, Francesco
    Cagnetti, Claudia
    Trinka, Eugen
    Silvestrini, Mauro
    CNS DRUGS, 2018, 32 (10) : 905 - 916
  • [43] Long-Term Safety And Efficacy Of Add-on Cannabidiol (CBD) Treatment in Patients With Lennox-Gastaut Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Chin, R.
    Patel, A.
    Gil-Nagel, A.
    Mitchell, W.
    Perry, M. S.
    Weinstock, A.
    Whyte, L.
    VanLandingham, K.
    EPILEPSIA, 2019, 60 : 63 - 64
  • [44] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5)
    Thiele, E.
    Marsh, E.
    Halford, J.
    Mazurkiewicz-Beldzinska, M.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    ANNALS OF NEUROLOGY, 2018, 84 : S336 - S336
  • [45] Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
    Knupp, Kelly G.
    Scheffer, Ingrid E.
    Ceulemans, Berten
    Sullivan, Joseph
    Nickels, Katherine C.
    Lagae, Lieven
    Guerrini, Renzo
    Zuberi, Sameer M.
    Nabbout, Rima
    Riney, Kate
    Agarwal, Anupam
    Lock, Michael
    Dai, David
    Farfel, Gail M.
    Galer, Bradley S.
    Gammaitoni, Arnold R.
    Polega, Shikha
    Davis, Ronald
    Gil-Nagel, Antonio
    EPILEPSIA, 2023, 64 (01) : 139 - 151
  • [46] Efficacy and Safety of Adjunctive Rufinamide in Lennox-Gastaut Syndrome (LGS): Results from Studies 022, 022E, 303, 304, and 305
    Arzimanoglou, Alexis
    Kluger, Gerhard
    Mueller, Arnd
    Ohtsuka, Yoko
    Williams, Betsy
    Bibbiani, Francesco
    Perdomo, Carlos
    Malhotra, Manoj
    NEUROLOGY, 2018, 90
  • [47] Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome
    Leahy, Jennifer T.
    Chu-Shore, Catherine J.
    Fisher, Janet L.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 673 - 681
  • [48] Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome
    Kessler, Sudha Kilaru
    McCarthy, Ann
    Cnaan, Avital
    Dlugos, Dennis J.
    EPILEPSY RESEARCH, 2015, 112 : 18 - 26
  • [49] Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan
    Ohtsuka, Yoko
    Yoshinaga, Harumi
    Shirasaka, Yukiyoshi
    Takayama, Rumiko
    Takano, Hiroki
    Iyoda, Kuniaki
    EPILEPSY RESEARCH, 2014, 108 (09) : 1627 - 1636
  • [50] Adjunctive vagus nerve stimulation therapy for Lennox-Gastaut Syndrome.
    Hosain, S
    Green, N
    EPILEPSIA, 2003, 44 : 123 - 123
12345